In this issue:
Better prognosis with early clearance of driver mutations after transplant
RR6 prognostic model predicts survival after six months of ruxolitinib
Direct transition from ruxolitinib to momelotinib may be beneficial
FREEDOM2: fedratinib efficacious for ruxolitinib refractory disease
Cytopenia does not impact the efficacy of pacritinib
Disease-modifying activity of navtemadlin correlates with clinical responses
Luspatercept improves anaemia and transfusion burden
Role of molecular alterations in transplantation decisions
Donor types and outcomes of transplantation in myelofibrosis
Allogeneic transplant may be a feasible therapy for geriatric patients
Please login below to download this issue (PDF)